JP2016503399A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016503399A5 JP2016503399A5 JP2015539782A JP2015539782A JP2016503399A5 JP 2016503399 A5 JP2016503399 A5 JP 2016503399A5 JP 2015539782 A JP2015539782 A JP 2015539782A JP 2015539782 A JP2015539782 A JP 2015539782A JP 2016503399 A5 JP2016503399 A5 JP 2016503399A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- cancer
- cetuximab
- administered
- leukemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261718430P | 2012-10-25 | 2012-10-25 | |
| US61/718,430 | 2012-10-25 | ||
| PCT/US2013/066564 WO2014066606A2 (en) | 2012-10-25 | 2013-10-24 | Combination |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016503399A JP2016503399A (ja) | 2016-02-04 |
| JP2016503399A5 true JP2016503399A5 (OSRAM) | 2016-12-08 |
Family
ID=50545472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015539782A Pending JP2016503399A (ja) | 2012-10-25 | 2013-10-24 | 組合せ |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20150273057A1 (OSRAM) |
| EP (1) | EP2911673A4 (OSRAM) |
| JP (1) | JP2016503399A (OSRAM) |
| KR (1) | KR20150070393A (OSRAM) |
| CN (1) | CN104812391A (OSRAM) |
| AU (1) | AU2013334599B2 (OSRAM) |
| BR (1) | BR112015009134A2 (OSRAM) |
| CA (1) | CA2889530A1 (OSRAM) |
| MX (1) | MX2015005307A (OSRAM) |
| RU (1) | RU2015119218A (OSRAM) |
| WO (1) | WO2014066606A2 (OSRAM) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9181243B2 (en) * | 2013-12-03 | 2015-11-10 | Hangzhou Pushai Pharmaceutical Technology Co. Ltd. | Solvate form M of trametinib dimethyl sulfoxide and methods of making and using thereof |
| WO2015087279A1 (en) * | 2013-12-12 | 2015-06-18 | Glaxosmithkline Intellectual Property (No.2) Limited | Combinations of trametinib, panitumumab and dabrafenib for the treatment of cancer |
| WO2016029002A2 (en) * | 2014-08-22 | 2016-02-25 | Clovis Oncology, Inc. | Growth factor receptor inhibitors |
| CA2944085C (en) * | 2014-09-16 | 2018-04-10 | Ease Charm Limited | Anti-egfr antibody and uses of same |
| WO2017019279A1 (en) * | 2015-07-27 | 2017-02-02 | Southern Research Institute | Methods and compositions to treat cancers involving egfr |
| EP3442572A1 (en) * | 2016-04-15 | 2019-02-20 | Eli Lilly and Company | Combination therapy of ramucirumab and abemaciclib for use in treatment of mantle cell lymphoma |
| MX387795B (es) * | 2016-06-03 | 2025-03-19 | Array Biopharma Inc | Combinaciones farmaceuticas. |
| RU2627692C1 (ru) | 2016-10-10 | 2017-08-10 | Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") | N-{ 3-[3-циклопропил-5-(2-фторо-4-иодофениламино)-6,8-диметил-2,4,7-триоксо-3,4,6,7-тетрагидро-2Н-пиридо[4,3-d]пиримидин-1-ил]-фенил} -циклопропанкарбоксамида диметилсульфоксида сольват в качестве ингибитора МЕК1/2 |
| KR102260995B1 (ko) * | 2018-11-28 | 2021-06-04 | 국립암센터 | Plk1의 활성 억제제를 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물 |
| CA3201657A1 (en) * | 2020-12-11 | 2022-06-16 | Leenus MARTIN | Combination therapies for the treatment of cancer |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1761528E (pt) * | 2004-06-11 | 2008-04-15 | Japan Tobacco Inc | Derivados de 5-amino-2,4,7-trioxo-3,4,7,8-tetra-hidro-2hpirido[ 2,3-d]pirimidina e compostos relacionados para o tratamento do cancro |
| US7378423B2 (en) * | 2004-06-11 | 2008-05-27 | Japan Tobacco Inc. | Pyrimidine compound and medical use thereof |
| WO2008101840A1 (en) * | 2007-02-23 | 2008-08-28 | F. Hoffmann-La Roche Ag | Combination of erlotinib and mek-inhibitors for inhibiting proliferation of tumor cells |
| US20110053879A1 (en) * | 2008-02-08 | 2011-03-03 | Poniard Pharmaceuticals, Inc. | Picoplatin and amrubicin to treat lung cancer |
| UA103319C2 (en) * | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
| RU2553379C2 (ru) * | 2009-08-24 | 2015-06-10 | Дженентек, Инк. | ОПРЕДЕЛЕНИЕ ЧУВСТВИТЕЛЬНОСТИ КЛЕТОК К ОБРАБОТКЕ ИНГИБИТОРОМ B-Raf ПУТЕМ ДЕТЕКЦИИ МУТАЦИИ K-ras И УРОВНЕЙ ЭКСПРЕССИИ RTK |
| HUE067723T2 (hu) * | 2009-10-16 | 2024-11-28 | Novartis Ag | MEK-inhibitort és B-Raf-inhibitort tartalmazó kombináció |
| US20130236449A1 (en) * | 2010-04-21 | 2013-09-12 | Ventirx Pharmaceuticals, Inc. | Methods of enhancing antibody-dependent cellular cytotoxicity |
| FR2968557A1 (fr) * | 2010-12-09 | 2012-06-15 | Sanofi Aventis | Combinaison antitumorale comprenant un derive de la famille des combretastatines et le cetuximab |
| US20130004481A1 (en) * | 2011-01-12 | 2013-01-03 | Boehringer Ingelheim International Gmbh | Anticancer therapy |
| MY181439A (en) * | 2011-02-28 | 2020-12-22 | Sunshine Lake Pharma Co Ltd | Substituted quinoline compounds and methods of use |
| US20140134158A1 (en) * | 2012-05-22 | 2014-05-15 | Alberto Bardelli | Kras mutations and resistance to anti-egfr treatment |
| TWI601725B (zh) * | 2012-08-27 | 2017-10-11 | 加拓科學公司 | 取代的氮雜吲哚化合物及其鹽、組合物和用途 |
| BR112015006176B1 (pt) * | 2012-09-21 | 2023-04-18 | Intensity Therapeutics, Inc | Uso de um agente terapêutico e de um agente de intensificação de permeação intracelular |
-
2013
- 2013-10-24 JP JP2015539782A patent/JP2016503399A/ja active Pending
- 2013-10-24 BR BR112015009134A patent/BR112015009134A2/pt not_active IP Right Cessation
- 2013-10-24 RU RU2015119218A patent/RU2015119218A/ru not_active Application Discontinuation
- 2013-10-24 KR KR1020157013212A patent/KR20150070393A/ko not_active Ceased
- 2013-10-24 EP EP13848440.7A patent/EP2911673A4/en not_active Withdrawn
- 2013-10-24 AU AU2013334599A patent/AU2013334599B2/en not_active Ceased
- 2013-10-24 CA CA2889530A patent/CA2889530A1/en not_active Abandoned
- 2013-10-24 WO PCT/US2013/066564 patent/WO2014066606A2/en not_active Ceased
- 2013-10-24 CN CN201380056222.9A patent/CN104812391A/zh active Pending
- 2013-10-24 MX MX2015005307A patent/MX2015005307A/es unknown
- 2013-10-24 US US14/437,231 patent/US20150273057A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016503399A5 (OSRAM) | ||
| RU2015119218A (ru) | Комбинация | |
| JP2013522212A5 (OSRAM) | ||
| RU2017102319A (ru) | Прерывистое введение ингибитора mdm2 | |
| RU2015154275A (ru) | Комбинации антитела против pd-l1 и ингибитора mek и/или ингибитора braf | |
| JP2017504611A5 (OSRAM) | ||
| JP2016528162A5 (OSRAM) | ||
| JP2016185995A5 (OSRAM) | ||
| JP2014507412A5 (OSRAM) | ||
| JP2016529245A5 (OSRAM) | ||
| JP2015096544A5 (OSRAM) | ||
| JP2019511526A5 (OSRAM) | ||
| JP2015536964A5 (OSRAM) | ||
| JP2006514689A5 (ja) | １−オキソ−２−（２，６−ジオキソピペリジン−３−イル）−４−メチルイソインドリンを含む脳腫瘍の治療及び管理のための医薬組成物 | |
| JP2012067116A5 (OSRAM) | ||
| JP2018168191A5 (OSRAM) | ||
| JP2015536986A5 (OSRAM) | ||
| JP2008521928A5 (OSRAM) | ||
| ME02663B (me) | Derivati benzimidazola kao inhibitori pi3 kinaze | |
| HRP20160361T1 (hr) | Terapija u kombinaciji s antitumorskim alkaloidom | |
| JP2013522326A5 (OSRAM) | ||
| JP2015529234A5 (OSRAM) | ||
| FI3577124T3 (fi) | Nukleotidihemisulfaattisuola hepatiitti C -viruksen hoitoon | |
| JP2009138003A5 (OSRAM) | ||
| CN111902417A (zh) | 一种二芳基巨环化合物、药物组合物以及其用途 |